Relay Therapeutics (RLAY) Stock: Buy, Sell, or Hold?
RLAY - Relay Therapeutics, Inc. Common Stock
$18.87
-0.02 (-0.11%)
▼
5d:
-0.74%
30d:
-5.98%
90d:
+32.51%
BUY
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When RLAY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RLAY shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RLAY shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RLAY is currently trading at $18.87, which is considered slightly low relative to its 30-day fair value range of $18.83 to $20.17.
Technical Outlook: Technically, RLAY is in a strong uptrend. The price is approaching resistance at $19.35. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RLAY scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $27.08 (+43.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RLAY is in a strong uptrend. The price is approaching resistance at $19.35. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RLAY scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $27.08 (+43.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$18.83 -
$20.17
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (62/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 43.5% below Wall St target ($27.08)
- BULLISH: Bottoming setup score 62/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$18.83 -
$20.17
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$17.96
Resistance Level
$19.35
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.53
Wall Street Target
$27.08
(+43.5%)
Revenue Growth (YoY)
-48.3%
Share & Embed Analysis
Last updated: September 11, 2026 8:33 PM ET
Data refreshes hourly during market hours. Next update: 9:33 PM
Data refreshes hourly during market hours. Next update: 9:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RLAY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Thomas Catinazzo
SELL
1800 shares
2026-04-09
Thomas Catinazzo
SELL
17717 shares
2026-04-07
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
